Recent study revealed that women who survived the dreadful breast cancer battle are highly at risk of leukemia, a deemed adverse effect of treatments because as they kill cancerous cells, they also tend to target healthy ones.
A cancer drug by Johnson & Johnson and AbbVie called Imbruvica can significantly decrease risk of death and slow down disease advancement with an estimated 84 percent lowered risk.